Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec 19:37:102240.
doi: 10.1016/j.ajoc.2024.102240. eCollection 2025 Mar.

Persistent bilateral sclerouveitis following bimatoprost implantation and removal

Cheng Jiao  1   2 , Ganesh Prabakaran  1 , Thomas Berk  3 , Homaira Ayesha Hossain  3 , Sruthi Arepalli  3
Affiliations
Case Reports

Persistent bilateral sclerouveitis following bimatoprost implantation and removal

Cheng Jiao et al. Am J Ophthalmol Case Rep. .

Abstract

Purpose: To report a case of persistent bilateral sclerouveitis following bilateral bimatoprost implantation (Durysta) that required implant removal and oral steroid course.

Observation: A 75-year-old Caucasian male with no prior ocular inflammation experienced bilateral sclerouveitis post bilateral bimatoprost implantation. Despite implant removal from both eyes, the ocular inflammation persisted, showing cystoid macular edema in both eyes and exudative retinal detachment in the right. A comprehensive assessment revealed no clear etiology and no definitive systematic inflammatory syndrome. The ocular inflammation was unresponsive to topical steroids and only receded following weeks-long course of oral steroids. Eventually, the patient required immunosuppression due to recurrence of the inflammation.

Conclusion and importance: The persistence and severity of this inflammatory response to bimatoprost implants, despite its removal, highlight the importance of considering patient-specific risk factors and tailoring management accordingly. Clinicians should be prepared for possible severe reactions requiring intervention.

Keywords: Bimatoprost implant; Prostaglandin; Sclerouveitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
A 75 year old Caucasian male with bilateral sclerouveitis following bilateral bimatoprost implantation. Late phase fluorescein angiography on presentation confirming disc leakage (white arrow) and macular leakage (orange arrow) right (A) and left eye (OS) (B), with staining of the peripheral chorioretinal scar OS (star). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
See this image and copyright information in PMC

References

    1. Durysta (bimatoprost implant) Package insert. Allergan. 2021
    1. Bacharach J., Tatham A., Ferguson G., et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2) Drugs. Nov 2021;81(17):2017–2033. doi: 10.1007/s40265-021-01624-9. - DOI - PMC - PubMed
    1. Weinreb R.N., Bacharach J., Brubaker J.W., et al. Bimatoprost implant biodegradation in the phase 3, randomized, 20-month ARTEMIS studies. J Ocul Pharmacol Therapeut. Jan-Feb 2023;39(1):55–62. doi: 10.1089/jop.2022.0137. - DOI - PMC - PubMed
    1. Kesav N.P., Young C.E.C., Ertel M.K., Seibold L.K., Kahook M.Y. Sustained-release drug delivery systems for the treatment of glaucoma. Int J Ophthalmol. 2021;14(1):148–159. doi: 10.18240/ijo.2021.01.21. - DOI - PMC - PubMed
    1. Seal J.R., Robinson M.R., Burke J., Bejanian M., Coote M., Attar M. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Therapeut. Jan/Feb 2019;35(1):50–57. doi: 10.1089/jop.2018.0067. - DOI - PMC - PubMed

Publication types

LinkOut - more resources